Lucy Mohapatra¹*, Sweta Mishra², Preeti Singh³, Pragya Srivastava³, Parul Mishra², Vivekanand Prajapati², Shivendra Misra², Richa Tripathi⁴ and NT Pramathesh Mishra³

¹Amity Institute of Pharmacy, Lucknow, Amity University, Uttar Pradesh, India
²Department of Pharmaceutics, Hygia College of Pharmacy, Dr APJ Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India
³Department of Pharmacology, Hygia College of Pharmacy, Dr APJ Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India
⁴Department of Pharmaceutics, Hygia Institute of Pharmacy, Dr APJ Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India

*Corresponding Author: MLucy Mohapatra, Amity Institute of Pharmacy, Lucknow, Amity University, Uttar Pradesh, India.

Received: May 15, 2023; Published: May 31, 2023

Abstract

Liquid biopsy, a non-invasive method of analyzing cancer biomarkers in blood and other bodily fluids, has emerged as a promising approach for cancer diagnosis and monitoring of treatment response. The three main types of liquid biopsy include circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs). Liquid biopsy offers several advantages over traditional tissue biopsy, including minimal invasiveness, ability to monitor disease progression in real-time, and potential for early cancer detection. However, challenges and limitations associated with liquid biopsy remain, such as the need for standardized protocols and assays, and the potential for false positives and negatives. Despite these challenges, liquid biopsy has shown great promise in clinical applications, such as monitoring of treatment response and resistance, and the identification of actionable mutations for targeted therapy. In conclusion, liquid biopsy holds great potential for improving cancer diagnosis and management, and ongoing research efforts will continue to refine and expand its clinical applications.

 Keywords: Liquid Biopsy; Cancer Diagnosis; Treatment Monitoring; Biomarkers; Personalized Medicine

References

1. O'Leary B., et al. “Treating cancer with selective CDK4/6 inhibitors”. Nature Reviews Clinical Oncology7 (2016): 417-430.
2. Pantel K and Alix-Panabières C. “Liquid biopsy and minimal residual disease - latest advances and implications for cure”. Nature Reviews Clinical Oncology5 (2019): 256-276.
3. Cabel L., et al. “Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study”. Annals of Oncology10 (2017): 1996-2001.
4. Diehl F., et al. “Circulating mutant DNA to assess tumor dynamics”. Nature Medicine9 (2008): 985-990.
5. Abbosh C., et al. “Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution”. Nature 7655 (2017): 446-451.
6. Snyder MW., et al. “Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin”. Cell 6 (2016): 57-68.
7. Cheng F., et al. “Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer”. Oncotarget 11 (2016): 48832-48841.
8. Thierry AR., et al. “Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA”. Nature Medicine4 (2014): 430-435.
9. Best MG., et al. “RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics”. Cancer Cell5 (2015): 666-676.
10. Siravegna G., et al. “Integrating liquid biopsies into the management of cancer”. Nature Reviews Clinical Oncology9 (2017): 531-548.
11. Park JY., et al. “Cell-free DNA derived from different tumor types exhibits a different fragment size pattern”. Cancer Research Treatment2 (2018): 492-500.
12. Chae YK., et al. “Concordance and discordance of genomic alterations in tissue and circulating tumor DNA in metastatic melanoma”. Clinical Cancer Research17 (2016): 4570-4578.
13. Huang X., et al. “Highly sensitive and specific analysis of cancer mutations using improved dynamic mutation detection (iDMD)”. Annals of Chemistry5 (2020): 3958-3965.
14. Zhang Q., et al. “Applications of liquid biopsy in breast cancer: biomarkers, circulating tumor cells, and circulating tumor DNA”. Journal of Breast Cancer1 (2021): 1-11.
15. Sheng Y., et al. “Comparing circulating tumor cells and circulating tumor DNA in patients with colorectal cancer receiving chemotherapy: an exploratory study”. Clinical Colorectal Cancer 2 (2020): 106-113.
16. Sanz-Castleblanco Á., et al. “Circulating tumor DNA and liquid biopsy: opportunities, challenges and prospects”. Clinica Chimica Acta 500 (2020): 80-92.
17. Kato S., et al. “Prospective monitoring of tumor-derived DNA in cerebrospinal fluid and neuroimaging to detect occult leptomeningeal disease of lung cancer”. Genome Medicine1 (2019): 44.
18. Wang Z., et al. “Liquid biopsy for gastric cancer: circulating tumor DNA and circulating tumor cells”. Translational Oncology12 (2020): 100853.
19. Lee M., et al. “Targeted sequencing and liquid biopsy approaches in lung cancer: a review”. Translational Lung Cancer Research3 (2021): 1407-1426.
20. Alegre E., et al. “Liquid biopsy in pancreatic cancer: current status and future directions”. Journal of Surgical Oncology6 (2020): 988-999.
21. Bai H., et al. “Liquid biopsy in tumors: opportunities and challenges”. Annals of Translational Medicine's17 (2018): 341.
22. Wu C., et al. “Detection of circulating tumor DNA in peripheral blood of lung cancer patients using whole genome sequencing”. Clinical Cancer Research9 (2015): 2096-2106.
23. Li X., et al. “The diagnostic value of liquid biopsy in oncogene-driven non-small cell lung cancer patients”. Frontiers in Oncology 11 (2021): 642984.
24. Kwapisz D. “The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?” Annals of Translational Medicine's6 (2017): 134.
25. Chaudhuri AA., et al. “Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling”. Cancer Discovery6 (2017): 1394-1403.
26. Schwaederle M., et al. “Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA”. (2016).
27. Chae YK., et al. “Concordance and discordance of somatic mutations and copy number changes between liquid and tissue biopsies in oncology”. Molecular Cancer Therapeutics5 (2017): 1073-1082.
28. Pantel K and Alix-Panabières C. “Liquid biopsy and minimal residual disease – latest advances and implications for cure”. Nature Reviews Clinical Oncology7 (2019): 409-424.
29. O'Leary B., et al. “Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis”. Clinical Chemistry11 (2019): 1405-1413.
30. Russo M., et al. “Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer”. Cancer Discovery2 (2016): 147-153.
31. Kinde I., et al. “Detection and quantification of rare mutations with massively parallel sequencing”. Proceedings of the National Academy of Sciences of the United States of America23 (2011): 9530-9535.
32. Wan JCM., et al. “Liquid biopsies come of age: towards implementation of circulating tumour DNA”. Nature Reviews Cancer4 (2017): 223-238.
33. Heitzer E., et al. “Current and future perspectives of liquid biopsies in genomics-driven oncology”. Nature Reviews Genetics2 (2019): 71-88.
34. Cohen JD., et al. “Detection and localization of surgically resectable cancers with a multi-analyte blood test”. Science6378 (2018): 926-930.
35. Siravegna G., et al. “Integrating liquid biopsies into the management of cancer”. Nature Reviews Clinical Oncology9 (2017): 531-548.
36. Murtaza M., et al. “Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA”. Nature 7447 (2011): 108-112.
37. Bettegowda C., et al. “Detection of circulating tumor DNA in early- and late-stage human malignancies”. Science Translational Medicine224 (2011): 224ra24.
38. Heitzer E., et al. “Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing”. Genome Medicine4 (2013): 30.
39. Minciacchi VR., et al. “Extracellular vesicles in cancer: exosomes, microvesicles and the emerging role of large oncosomes”. Seminars in Cell and Developmental Biology 40 (2015): 41-51.
40. Zocco D., et al. “Extracellular Vesicles as shuttles of tumor biomarkers and Anti-tumor drugs in Cancer Therapy”. International Journal of Molecular Sciences8 (2019): 1848.

Citation

Citation: Lucy Mohapatra., et al. “The Potential of Liquid Biopsy in Cancer Diagnosis and Monitoring of Treatment Response" Acta Scientific Cancer Biology 7.4 (2023): 42-52.

Copyright

Copyright: © 2023 Lucy Mohapatra., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.